Discover
Biotech CEO Sisterhood
Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership

Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership
Update: 2025-08-19
Share
Description
Interviewed by Xilio Therapeutics President & CEO René Russo, Dr. Liebisch describes her start in the industry as a patent attorney, discusses why having a champion in a larger partner is key, and explains why she even once threw a party when Vigil discontinued a candidate. Vigil Neuroscience was acquired by Sanofi earlier this year for an equity value representing approximately $470 million, plus a CVR.
Comments
In Channel






















